Tarlatamab
20200041
Phase 3 small_molecule active
Quick answer
Tarlatamab for Extensive-Stage Small-Cell Lung Cancer is a Phase 3 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen
- Indication
- Extensive-Stage Small-Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active